SCHEMBL610592

SCHEMBL610592

O=C(O)c1c(Cl)cc(Cl)c(O)c1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
GPR35 Q9HC97 2/20 0.43
ALDH1A1 P00352 2/20 0.42
TTR P02766 1/20 0.42
DPP4 P27487 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CDK2 P24941 1/20 0.40
GRIN2D O15399 4/20 0.40
GRIN3B O60391 4/20 0.40
GRIN1 Q05586 4/20 0.40
GRIN2A Q12879 4/20 0.40
GRIN2B Q13224 4/20 0.40
GRIN2C Q14957 4/20 0.40
GRIN3A Q8TCU5 4/20 0.40
AKR1C4 P17516 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
AKR1C1 Q04828 1/20 0.39
CYP1A2 P05177 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29186004 0.86 AKR1C2 (0.44) TSHRGPR35ALDH1A1TTRDPP4
SCHEMBL29185997 0.85 ALDH1A1 (0.46) TSHRGPR35ALDH1A1TTRDPP4
SCHEMBL3239188 0.84 TSHR (0.46) TSHRGPR35ALDH1A1GRIN2DGRIN3B
SCHEMBL9132988 0.82 TSHR (0.60) TSHRGPR35ALDH1A1GRIN2DGRIN3B
SCHEMBL1477313 0.81 ALDH1A1 (0.54) TSHRALDH1A1DPP4CA1CA2
SCHEMBL17344236 0.81 ALDH1A1 (0.47) TSHRALDH1A1CA1CA2CDK2
SCHEMBL31470133 0.80 SMN1; SMN2 (0.49) TSHRGPR35ALDH1A1CA1CA2
SCHEMBL7902778 0.80 SMN1; SMN2 (0.49) TSHRGPR35ALDH1A1CA1CA2
SCHEMBL8563644 0.80 TSHR (0.53) TSHRGPR35ALDH1A1DPP4CA1
SCHEMBL27739227 0.80 CRHBP (0.43) ALDH1A1DPP4CDK2AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117586126-A Synthesis method of 4, 6-dichloro-3-hydroxy-2-nitrobenzoic acid 扬州市荣晶新材料科技有限公司 2024-02-23 CN claimed
CN-117586126-A Synthesis method of 4, 6-dichloro-3-hydroxy-2-nitrobenzoic acid 扬州市荣晶新材料科技有限公司 2024-02-23 CN disclosed
CN-117586126-A Synthesis method of 4, 6-dichloro-3-hydroxy-2-nitrobenzoic acid 扬州市荣晶新材料科技有限公司 2024-02-23 CN disclosed
CN-117586126-A Synthesis method of 4, 6-dichloro-3-hydroxy-2-nitrobenzoic acid 扬州市荣晶新材料科技有限公司 2024-02-23 CN disclosed
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 EP disclosed
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 EP disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-20080119470-A1 Neurologically-Active Compounds XOMA TECHNOLOGY LTD. 2008-05-22 US disclosed
US-20060167000-A1 Neurologically-active compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2006-07-27 US disclosed
WO-2005095360-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2005-10-13 WO disclosed
EP-1558585-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS Prana Biotechnology Ltd (AU) 2005-08-03 EP disclosed
WO-2004031161-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2004-04-15 WO disclosed
EP-0686145-B1 NEW COMPOUNDS UNIV MARYLAND (US) 2000-01-26 EP disclosed
US-5883129-A Hydroxylated anthranilic acid derivatives ASTRA AKTIEBOLAG (SE) 1999-03-16 US disclosed
US-5523475-A New compounds AKTIEBOLAGET ASTRA (SE) 1996-06-04 US disclosed
EP-0686145-A1 NEW COMPOUNDS AKTIEBOLAGET ASTRA (SE) 1995-12-13 EP disclosed
WO-1994019316-A1 NEW COMPOUNDS AKTIEBOLAGET ASTRA (SE) 1994-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NDUFV2 TSHR 3537/4885GPR35 1836/4885ALDH1A1 866/4885
US-20080119470-A1 Neurologically-Active Compounds ACHE, PSEN1, PSEN2 TSHR 4660/4885GPR35 1767/4885ALDH1A1 1120/4885
US-20060167000-A1 Neurologically-active compounds ACHE, PSEN1, PSEN2 TSHR 4668/4885GPR35 2744/4885ALDH1A1 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.